default author photo

Adam Meijer

National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control

Bilthoven

Netherlands

  • National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control

SCHOLARLY PAPERS

7

DOWNLOADS

614

TOTAL CITATIONS

2

Scholarly Papers (7)

Actions:
Email selected abstracts
1.

Effectiveness of Covid-19 Vaccines Administered in the 2023 Autumnal Campaigns in Europe: Results from the Vebis Primary Care Test-Negative Design Study, September 2023–January 2024

Number of pages: 27 Posted: 01 May 2024
Charlotte Lanièce Delaunay, Aryse Melo, Marine Maurel, Clara Mazagatos, Luise Goerlitz, Joan O'Donnell, Beatrix Oroszi, Noémie Sève, Ana Paula Rodrigues, Iván Martínez-Baz, Adam Meijer, Ivan Mlinarić, Neus Latorre-Margalef, Mihaela Lazar, Gloria Pérez-Gimeno, Ralf Dürrwald, Charlene Bennett, Gergő Túri, Marie-Anne Rameix Welti, Raquel Guiomar, Jesús Castilla, Mariëtte Hooiveld, Sanja Kurečić Filipović, Tove Samuelsson Hagey, Frederika Dijkstra, Vítor Borges, Violeta Ramos Marín, Sabrina Bacci, Marlena Kaczmarek and Esther Kissling
Epiconcept, National Institute of Health Doutor Ricardo Jorge, Epiconcept, Carlos III Institute of Health - Communicable Diseases Department, Robert Koch Institute, Health Service Executive, Semmelweis University, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, Croatian Institute of Public Health, Public Health Agency of Sweden, Romanian Institute of Science and Technology - National Institute of Research and Development for Microbiology and Immunology „Cantacuzino”, Carlos III Health Institute, Robert Koch Institute, University College Dublin (UCD), Semmelweis University, University of Paris-Saclay - Laboratoire de Microbiologie, National Health Institute Doutor Ricardo Jorge (INSA) - National Influenza Reference Laboratory, Instituto de Salud Pública y Laboral de Navarra, NIVEL (Netherlands Institute for Health Services Research), Croatian Institute of Public Health, Public Health Agency of Sweden, National Institute for Public Health and the Environment (RIVM), National Health Institute Doutor Ricardo Jorge (INSA) - Bioinformatics Unit, Consejería de Sanidad, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 137 (534,155)
Citation 2

Abstract:

Loading...

COVID-19, vaccine effectiveness, multicentre study, test-negative design, Europe, SARS-CoV-2

2.

COVID-19 Vaccine Effectiveness Among Older Adults in 2025/26

Number of pages: 16 Posted: 12 Mar 2026 Last Revised: 20 Mar 2026
Charlotte Lanièce Delaunay, Alberto Mateo Urdiales, Gloria Pérez-Gimeno, Karen O’Reilly, Marina Uras, Annika Erdwiens, Ivan Mlinarić, Gergő Túri, Adam Meijer, Ana Paula Rodrigues, Mihaela Lazar, Neus Latorre-Margalef, Héloïse Lucaccioni, Nuno Verdasca, Antonino Bella, Maria Angeles Rafael de la Cruz Lopez, Eva Kelly, Vincent Enouf, Kristin Tolksdorf, Simona Puzelli, Ana Carmen Ibañez, Iván Martínez-Baz, Margaret Fitzgerald, Shirley Masse, Djin-Ye Oh, Marlena Kaczmarek, Sabrina Bacci and Esther Kissling
Epiconcept, Bruno Kessler Foundation, Carlos III Health Institute, Health Protection Surveillance Centre (HPSC), Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Robert Koch Institute - Department for Infectious Disease Epidemiology, Croatian Institute of Public Health, Semmelweis University, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Cantacuzino National Military Medical Institute for Research and Development, Public Health Agency of Sweden, Epiconcept, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Istituto Superiore di Sanità, The Directorate General of Public Health, The Health Service Executive-Health Protection Surveillance Centre (HSE-HPSC), University of Paris-Saclay - Institut Pasteur, Robert Koch Institute - Department for Infectious Disease Epidemiology, Istituto Superiore di Sanità - Department of Infectious Diseases, Consejería de Sanidad - Dirección General de Salud Pública, Instituto de Salud Pública y Laboral de Navarra, The Health Service Executive-Health Protection Surveillance Centre (HSE-HPSC), University of Corsica, Robert Koch Institute, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 119 (674,591)

Abstract:

Loading...

COVID-19, SARS-CoV-2, Vaccine effectiveness, Europe

3.

COVID-19 Vaccine Effectiveness against Medically Attended Symptomatic SARS-CoV-2 Infection among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network

Number of pages: 20 Posted: 21 Mar 2025
Charlotte Lanièce Delaunay, Nuno Verdasca, Susana Monge, Lisa Domegan, Noémie Sève, Silke Buda, Adam Meijer, Héloïse Lucaccioni, Miriam López Torrijos, Adele McKenna, Vincent Enouf, Ralf Dürrwald, Eline In‘t Velt, Mª Ángel Valcárcel de Laiglesia, Charlene Bennett, Shirley Masse, Annika Erdwiens, Mariëtte Hooiveld, Ivan Mlinarić, Gergő Túri, Ana Paula Rodrigues, Iván Martínez-Baz, Mihaela Lazar, Neus Latorre-Margalef, Vítor Borges, Marlena Kaczmarek, Sabrina Bacci and Esther Kissling
Epiconcept, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Carlos III Institute of Health - Communicable Diseases Department, Health Protection Surveillance Centre (HPSC), Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Robert Koch Institute, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, Epiconcept, Subdirección General de Epidemiología y Vigilancia de la Salud, Health Service Executive, University of Paris-Saclay - Institut Pasteur, Robert Koch Institute, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, Murcia Regional Health Council-IMIB, University College Dublin (UCD), University of Corsica, Robert Koch Institute - Department for Infectious Disease Epidemiology, NIVEL (Netherlands Institute for Health Services Research), Croatian Institute of Public Health, Semmelweis University, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, Cantacuzino National Military Medical Institute for Research and Development, Public Health Agency of Sweden, National Health Institute Doutor Ricardo Jorge (INSA) - Bioinformatics Unit, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 109 (649,907)

Abstract:

Loading...

COVID-19, vaccine effectiveness, SARS-CoV-2, Europe

4.

Effectiveness of XBB.1.5 Vaccines against Symptomatic SARS-CoV-2 Infection in Older Adults during the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024

Number of pages: 17 Posted: 11 Jul 2024
Lore Merdrignac, Charlotte Lanièce Delaunay, Nuno Verdasca, Lorena Vega-Pirisc, Joan O’Donnell, Noémie Sève, Camino Trobajo-Sanmartín, Silke Buda, Mariëtte Hooiveld, Ana Paula Rodrigues, Gergő Túri, Neus Latorre-Margalef, Ivan Mlinarić, Mihaela Lazarm, Marine Maurel, Daniel Castrillejo, Charlene Bennett, Marie-Anne Rameix Welti, Iván Martínez-Baz, Ralf Dürrwald, Adam Meijer, Aryse Melo, Beatrix Oroszi, Tove Samuelsson Hagey, Sanja Kurečić Filipović, Frederika Dijkstra, Verónica Gomez, Sabrina Bacci, Marlena Kaczmarek and Esther Kissling
Epiconcept - Epidemiology Department, Epiconcept, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Carlos III Institute of Health, Health Protection Surveillance Centre (HPSC), Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, Robert Koch Institute, NIVEL (Netherlands Institute for Health Services Research), National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Semmelweis University, Public Health Agency of Sweden, Croatian Institute of Public Health, Cantacuzino National Military Medical Institute for Research and Development, Epiconcept, Consejería de Sanidad - Dirección General de Salud Pública, University College Dublin (UCD), University of Paris-Saclay - Laboratoire de Microbiologie, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, Robert Koch Institute, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, National Institute of Health Doutor Ricardo Jorge, Semmelweis University, Public Health Agency of Sweden, Croatian Institute of Public Health, National Institute for Public Health and the Environment (RIVM), National Institute of Health Doutor Ricardo Jorge, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 106 (664,543)

Abstract:

Loading...

COVID-19, SARS-CoV-2, Vaccine effectiveness, Primary care, Case-control study, Test-negative design, Multi-country study

5.

Interactions between Live Attenuated Influenza Vaccine and the Nasopharyngeal Microbiota Among Children Aged 24-59 Months in the Gambia: A Phase IV Open Label, Randomised Controlled Clinical Trial

Number of pages: 31 Posted: 07 Feb 2023
Chikondi Peno, Ya Jankey Jagne, Melanie Clerc, Carlos Lopez Balcazar, Edwin Armitage, Hadijatou Sallah, Sainabou Drammeh, Elina Senghore, Gabriel Goderski, Sophie von Tol, Adam Meijer, Alicia Ruiz-Rodriguez, Wouter de Steenhuijsen Piters, Emma M. de Koff, Sheikh Jarju, Benjamin B. Lindsey, Janko Camara, Sulayman Bah, Nuredin I. Mohammed, Beate Kampmann, Ed Clarke, David H. Dockrell, Thushan I. de Silva and Debby Bogaert
University of Edinburgh - Centre for Inflammation Research, London School of Hygiene & Tropical Medicine - Vaccines and Immunity Theme, University of Edinburgh - Centre for Inflammation Research, University of Edinburgh - Queen’s Medical Research Institute, London School of Hygiene & Tropical Medicine - Vaccines and Immunity Theme, London School of Hygiene & Tropical Medicine - Vaccines and Immunity Theme, London School of Hygiene & Tropical Medicine - Vaccines and Immunity Theme, London School of Hygiene & Tropical Medicine - Vaccines and Immunity Theme, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, University of Edinburgh - Centre for Inflammation Research, Utrecht University - University Medical Center (Utrecht), Spaarne Gasthuis, London School of Hygiene & Tropical Medicine - Vaccines and Immunity Theme, University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease, London School of Hygiene & Tropical Medicine - Vaccines and Immunity Theme, London School of Hygiene & Tropical Medicine - Vaccines and Immunity Theme, London School of Hygiene & Tropical Medicine - Vaccines and Immunity Theme, London School of Hygiene & Tropical Medicine - Vaccines and Immunity Theme, London School of Hygiene & Tropical Medicine - Vaccines and Immunity Theme, University of Edinburgh - Centre for Inflammation Research, University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease and University of Edinburgh - Queen’s Medical Research Institute
Downloads 98 (704,534)

Abstract:

Loading...

Live attenuated influenza vaccine, nasopharyngeal microbiota, vaccine immunogenicity-bacterial microbiota interactions, viral-bacterial microbiota interaction

6.

Evaluation of Molecular Detection for Respiratory Syncytial Viruses in World Health Organization Europe Region Laboratories, 2020-2023

Number of pages: 22 Posted: 14 May 2025
Lance D. Presser, Amani Yousef, Elaine McCulloch, Julia Schaumburg, Julia Schaumburg and Adam Meijer
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, VU University AmsterdamTinbergen Institute and National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control
Downloads 26 (1,385,945)

Abstract:

Loading...

PROMISE, respiratory syncytial virus, EQA, quality assessment, molecular diagnostics, QCMD

7.

Zoonotic Influenza Preparedness: Dutch Medical Labs Efficiently Detect Animal Influenza A Viruses - External Quality Assessment, 2023

Number of pages: 27 Posted: 05 Dec 2025
Samantha Zoomer, Gabriel Goderski, Sharon van den Brink, Lance D. Presser, Zandra C. Felix Garza, Oanh Vuong, Erhard van der Vries, Manon Houben, Ron Fouchier, Dirk Eggink and Adam Meijer
affiliation not provided to SSRN, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Erasmus University Rotterdam (EUR) - Department of Viroscience, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control and National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control
Downloads 19 (1,470,786)

Abstract:

Loading...

zoonotic influenza virus, preparedness, external quality assessment, Molecular Diagnostics, clinical laboratory, H5N1